galcanezumab

Contraindicated in:

Hypersensitivity.

Use Cautiously in:

OB: Safety not established in pregnancy;
Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant;
Pedi: Safety and effectiveness not established in children.

Adv. Reactions/Side Effects ⬆ ⬇

Local: injection site reactions

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)

Interactions ⬆ ⬇

Drug-drug:

None reported.

Availability ⬆ ⬇

Solution for injection (prefilled pens and prefilled syringes): 100 mg/mL; 120 mg/mL

Route/Dosage ⬆ ⬇

Migraine Prevention

SC (Adults ): 240 mg once initially as loading dose, then 120 mg once monthly.

Episodic Cluster Headache

SC (Adults ): 300 mg once at the onset of the cluster period, then 300 mg once monthly until the end of the cluster period.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor, which reduces the neuroinflammatory and vasodilatory effects of CGRP.

Therapeutic effects:

Reduction in frequency of migraines and cluster headaches.

Classifications ⬆ ⬇

Therapeutic Classification: vascular headache suppressants

Pharmacologic Classification: monoclonal antibodies, calcitonin gene-related peptide receptor antagonists

Pharmacokinetics ⬆ ⬇

Absorption: Unknown.

Distribution: Some tissue distribution.

Metabolism/Excretion: Degraded into small peptides and amino acids via catabolic pathways.

Half-Life: 27 days.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
SUBQ	unknown	5 days	1 mo

Patient/Family Teaching ⬆ ⬇

Explain purpose and side effects of medication. Advise patient to read Patient Information before starting therapy.
Instruct patient on correct technique for preparation, SUBQ injection and disposal of equipment.
Instruct patient to notify health care provider immediately if signs and symptoms of hypersensitivity reaction (itching; rash; hives; swelling of face, mouth, tongue, or throat; trouble breathing) occur.
Advise patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care provider before taking other medications.
Rep: Advise women of reproductive potential to notify health care provider if pregnancy is planned or suspected or if breastfeeding. Inform patient of pregnancy exposure registry. Health care providers or the pregnant patient may enroll by calling 1-833-464-4724 or visiting www.migrainepregnancyregistry.com.

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇